Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Estramustine and Hormone Therapy for Rising PSA Prostate Cancer
NCT00165399Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2004
- Primary completion
- Dec 2005
- Modality
- Peptides, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, estramustine, bicalutamide and goserelin in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Feasibility of administering chemotherapy and medical castration at 2 years. Started Mar 2004; status: completed.
02
Drugs
docetaxelestramustinebicalutamidegoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00165399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00165399.